The epidemiologic burden of hepatitis C virus infection in latin america

Annals of Hepatology

Volumn 11, Issue 5, 2012, Pages 623-635

  Szabo, Shelagh M ^a   Bibby, Meagan ^a   Yuan, Yong ^b   Donato, Bonnie M K ^b   Jimenez Mendez R ^c   Castaneda Hernandez G ^d   Rodríguez Torres, Maribel ^e   Levy, Adrian R ^a,f  

^a ICON PLC   (United Kingdom)

^b BRISTOL MYERS SQUIBB   (United States)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d DEPARTAMENTO DE FÍSICA   (Mexico)

^e Fundación de Investigación de Diego   (United States)

^f DALHOUSIE UNIVERSITY   (Canada)

Author keywords

Burden; HCV; Liver disease; Prevalence; Systematic review

Indexed keywords

BLOOD DONOR; GENOTYPE; HEPATITIS C; HUMAN; MORBIDITY; POPULATION RESEARCH; PREVALENCE; REVIEW; SOUTH AND CENTRAL AMERICA; SYSTEMATIC REVIEW; TREATMENT RESPONSE;

EID: 84865315523     PISSN: 16652681     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1665-2681(19)31435-8     Document Type: Review

References (86)

1. World Health Organization. Hepatitis C: Fact Sheet No. 164. World Health Organization 2011; Available from: http://www.who.int/mediacentre/factsheets/fs164/en/index.html
2. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001; 345: 41-52.
3. US Department of Health and Human Services. Centers for Disease Control and Prevention. Recommendations for Prevention and Control for Hepatitis C Virus (HCV) Infection and HCV Related Chronic Disease. 1998. Report No.: 47.
4. Torresi J, Johnson D, Wedemeyer H. Progress in the development of preventive and therapeutic vaccines for hepatitis C virus. J Hepatol 2011.
5. American Association for the Study of Liver Disease (AASLD). HBV & HCV: America's Hidden Epidemics. 2010 Jan 9.
6. Kershenobich D, Razavi HA, Sanchez-Avila JF, Bessone F, Coelho HS, Dagher L, Goncales FL, et al. Trends and projections of hepatitis C virus epidemiology in Latin America. Liver Int 2011; 31(Suppl. 2): 18-29.
7. Te HS, Jensen DM. Epidemiology of hepatitis B and C viruses: a global overview. Clin Liver Dis 2010; 14: 1-21, vii.
8. Rodriguez-Torres M, Jeffers LJ, Sheikh MY, Rossaro L, Ankoma-Sey V, Hamzeh FM, Martin P. Peginterferon alfa-2a and ribavirin in Latino and non-Latino whites with hepatitis C. N Engl J 2009; 360: 257-267.
9. Dehesa-Violante M, Nunez-Nateras R. Epidemiology of Hepatitis Virus B and C. Archives of Medical Research 2007; 38: 606-611.
10. Jiménez-Méndez R, Uribe-Salas F, López-Guillen P, Cisne-ros-Garza L, Castaneda-Hernandez G. Distribution of HCV genotypes and HCV RNA viral load in different regions of Mexico. Ann Hepatol 2010; 9: 33-39.
11. Sanchez-Avila JF, Gonzalez E, Vazquez V, Suarez S, Uribe M. Geographical distribution of HCV genotypes in Mexico. Ann Hepatol 2007; 6: 156-160.
12. Kwo PY. Response-guided Therapy for HCV. Gastroentero-logy and Hepatology 2011; 7: 43-45.
13. Pan American Health Organization. Supply of blood for transfusion in the Caribbean and Latin American countries in 2006 and 2007: Progress since 2005 of the Regional Plan of Action for Transfusion Safety. 2009.
14. Pan American Health Organization (PAHO) Technology and Health Services Delivery Area. Essential Medicines VaHT. Supply of blood for transfusion in the Caribbean and Latin American countries in 2005: Base line data for the Regional Plan of Action for Transfusion Safety 2006-2010. Washington, DC: PAHO; 2005.
15. Ministerio de Salud. Ministry of Health, Argentina. Ministerio de Salud 2011. Available from: http://www.msal.gov.ar/htm/site/Default.asp
16. Dirección de Estadística e Información de Salud. Sistema Nacional de Vigilancia Epidemiológica, SINAVE. Dirección de Estadística e Información de Salud 2011. Available from: http://www.msal.gov.ar/htm/site/estadisticas.asp
17. Agencia Nacional de Vigilancia Sanitaria. National Agency for Health Surveillance (ANVISA). Agencia Nacional de Vigi-lancia Sanitaria 2011. Available from: http:// websphere.anvisa.gov.br/wps/portal/anvisa/home/!ut/ p/c5/04_SB8K8xLLM9MSSzPy8xBz9CP0os3hnd0cPE3MfAwM DMydnA093Uz8z00B_AwN_Q_1wkA48Kowg8gY4gKOBvp9Hfm6qfk F2dpqjo6IiAJYj_8M!/dl3/d3/L2dBISEvZ0FBIS9nQSEh/
18. Information System of Notifiable Diseases. Sistema de Informação de Agravos de Notificação (SINAN). Information System of Notifiable Diseases 2011. Available from: http://dtr2004.saude.gov.br/sinanweb/index.php
19. Vivas-Arceo C, Benavides SA, De Jesus TJ, Panduro A, Ri-vas-Estilla AM. Hepatitis C virus: Prevalence and routes of infection among blood donors of West Mexico. Hepatology Research 2003; 25: 115-123.
20. Instituto Nacional de Salud Pública de México. Encuesta Nacional de Salud y Nutrición-ENSANUT 2006. Instituto Na-cional de Salud Pública de México 2010. Available from: URL: http://www.insp.mx/ensanut/
21. Encuesta Nacional de Salud (ENSA) Instituto Nacional de Salud Pública (INSP). ENSA 2000, national results, data on file. 2000.
22. Hoofnagle JH. Course and outcome of hepatitis C. Hepato-logy 2002 November; 36(5 Suppl. 1): S21-S29.
23. Insua JT, O'Flaherty M, Frontera Vacca MJ, Camino A, Maria Pia R, Silva M. HCV infection prevalence in Argentine and impact of unsage health care parenteral practices (HC-UPP): a seroprevalence survey. Society of General Internal Medicine 28th Annual General Meeting. 2003.
24. El KM, Cordeiro Q, Da Luz DABP, Duarte LS, Gama MEA, Corbett CEP. Endemic hepatitis B and C virus infection in a Brazilian Eastern Amazon region. Arquivos de Gastroen-terologia 2010; 47: 35-41.
25. Ministerio de Salud. Implementación de unidades centine-la: Hepatitis virales. 2002.
26. Ximenes RA, Pereira LM, Martelli CM, Merchan-Hamann E, Stein AT, Figueiredo GM, Braga MC, et al. Methodology of a nationwide cross-sectional survey of prevalence and epidemiological patterns of hepatitis A, B and C infection in Brazil. Cad Saude Publica 2010; 26: 1693-1704.
27. Ministerio da Saude. Secretaría de Vigilancia em Saude. Departmento de DST A. Brazil. Health Ministry. Health Surveillance Secretary. Department of STDs, AaVH, Brazil. 2010.
28. Focaccia R, Conceicao O, Sette H, Sabino E, Bassit L, Ni-trini D, et al. Estimated prevalence of viral hepatitis in the general population of the municipality of São Paulo, measured by a serologic survey of a stratified, randomized and residence-based population. Brazilian J Infectious Diseases 1998; 2: 269-284.
29. Zarife MA, Silva LK, Silva MB, Lopes GB, Barreto ML, Teixeira MG, Dourado I, Reis MG. Prevalence of hepatitis C virus infection in north-eastern Brazil: a population-based study. Trans R Soc Trop Med Hyg 2006; 100: 663-668.
30. Gonzalez R, Soza A, Hernandez V, Perez RM, Alvarez M, Morales A, Arellano M, et al. Incidence and prevalence of hepatitis C virus infection in Chile. Ann Hepatol 2005; 4: 127-130.
31. Valdespino JL, Conde-Gonzalez CJ, Olaiz-Fernandez G, Pal-ma O, Kershenobich D, Sepulvida J. Seroprevalencia de la hepatitis C en adultos de México: un problema de salud pú-blica emergente. Sal Pub Mex 2007; 49: S395-S403.
32. Méndez-Sánchez N, Ponciano-Rodríguez G, Chávez-Tapia NC, Motola-Kuba D, Meda-Valdes P, Sanchez-Lara K, Ramos MH, Uribe M. Prevalence of hepatitis C infection in a population of asymptomatic people in a checkup unit in Mexico city. Digestive Diseases & Sciences 2005; 50: 733-737.
33. Benitez-Arvizu G, Cortez-Gómez R, Novelo-Garza B, Malagon-Martínez A, Guerra-Márquez A, Alvarado-Maldonado M, et al. Prevalencia del virus de hepatitis C: en el banco de sangre del Centro Médico Nacional La Raza. Rev Med IMSS 2005; 44: 227-233.
34. García FB, Pereira GA, Martins PR, Moraes-Souza H. Epidemiological profile of hepatitis C in blood donors at the Uberaba Regional Blood Center. Revista Da Sociedade Brasileira de Medicina Tropical 2009; 42: 1-4.
35. Andrade AF, Oliveira-Silva M, Silva SG, Motta IJ, Bonvicino CR. Seroprevalence of hepatitis B and C virus markers among blood donors in Rio de Janeiro, Brazil, 1998-2005. Memorias do Instituto Oswaldo Cruz 2006 September; 101: 673-676.
36. Valente VB, Covas DT, Passos AD. Hepatitis B and C serologic markers in blood donors of the Ribeirao Preto Blood Center. [Portuguese]. Revista Da Sociedade Brasileira de Medicina Tropical 2005; 38: 488-492.
37. Salles NA, Sabino EC, Barreto CC, Barreto AM, Otani MM, Chamone DF. The discarding of blood units and the prevalence of infectious diseases in donors at the Pro-Blood Foundation/Blood Center of Sao Paulo, Sao Paulo, Brazil. [Portuguese]. Pan American Journal of Public Health 2003; 13: 111-116.
38. Rosini N, Mousse D, Spada C, Treitinger A. Seroprevalence of HbsAg, Anti-HBc and anti-HCV in Southern Brazil, 1999-2001. Brazilian J Infectious Diseases 2003; 7: 262-267.
39. Oliveira-Filho AB, Pimenta AS, Rojas MF, Chagas MC, Cres-cente JA, Crespo DM, Lemos JA. Prevalence and genotyping of hepatitis C virus in blood donors in the state of Para, Northern Brazil. Mem Inst Oswaldo Cruz 2010; 105: 103-106.
40. Torres K, Tateno A, Lima T, Malheiro A, Morais M, Levi J, et al. Characterization of hepatitis C virus infection in Amazon blood donors, Brazil. Vox Sanguinis 2010; 99(Supp. 1): 297.
41. de Almeida Neto C, Sabino E, Liu J, Mendrone-Junior A, Sa-lles N, Barros E, et al. Current prevalence and incidence of serologic markers for hepatitis C and prevalence of HBsAg among blood donors in Brazil. Transfusion 2010; 50(Suppl.): 202A.
42. Nascimento MC, Mayaud P, Sabino EC, Torres KL, Frances-chi S. Prevalence of hepatitis B and C serological markers among first-time blood donors in Brazil: A multi-center serosurvey. J Medical Virology 2008; 80: 53-57.
43. Levi J, Wendel S, Takaoka D, Foglietto M. Results of routine screening of Brazilian blood donors with the Roche Co-bas S 201/TAQSCREEN MPX System. Vox Sanguinis 2010; 99(Suppl. 1): 88.
44. Rivera-Lopez MR, Zavala-Mendez C, Renas-Esqueda A. Prevalence for seropositivity for HIV, hepatitis B and hepatitis C in blood donors. [Spanish]. Gaceta Médica de México 2004;140: 657-660.
45. Sosa-Jurado F, Santos-López G, Guzmán-Flores B, Ruiz-Con-de JI, Meléndez-Mena D, Vargas-Maldonado MT, Martinez-Laguna Y, et al. Hepatitis C virus infection in blood donors from the state of Puebla, Mexico. Virol J 2010; 7: 18.
46. Vazquez-Flores JA, Valiente-Banuet L, Lopez RA, Sanchez-Guerrero SA. Safety of the blood supply in Mexico from 1999 to 2003. [Spanish]. Rev Invest Clin 2006; 58: 101-108.
47. Farfan G, Cabezas C. Prevalence of viral hepatitis type C in blood donors in Peru. [Spanish]. Rev Gastroenterol Peru 2003; 23: 171-176.
48. Latin American Association for the Study of the Liver Practice Guidelines. Diagnosis, management, and treatment of hepatitis C. Ann Hepatol 2010; 9(Suppl.): 8-26.
49. The Global Burden of Hepatitis. Global Burden of Disease (GBD) for Hepatitis C. J Clin Pharmacol 2004; 44: 20-29.
50. Mendez-Sanchez N, Gutierrez-Grobe Y, Kobashi-Margain RA. Epidemiology of HCV infection in Latin America. Ann Hepatol 2010; 9(S1): S27-S29.
51. Dávalos Moscol M. Epidemiology of hepatitis C virus in Peru and Latin America [Spanish]. Rev Gastroenterol Peru 2009; 29: 347-354.
52. Jimenez-Mendez R, Castaneda-Hernandez G. Characteristics of hepatitis C treatment with pegylated interferons and ribavirin. Ann Hepatol 2010; 9(Suppl.): 61-64.
53. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shi-ffman M, Reindollar R, Goodman ZD, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. The Lancet 2001; 358(9286): 958-965.
54. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr., Haussinger D, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-982.
55. Hepburn MJ, Hepburn LM, Cantu NS, Lapeer MG, Lawitz EJ. Differences in treatment outcome for hepatitis C among ethnic groups. Am J Med 2004; 117: 163-168.
56. Munoz H, Arroyo J, Torres EA, De Jesus-Monge WE, Chinea B, Gonzalez H, Aponte N, et al. Response to combination therapy of interferon alfa-2b plus ribavirin in Hispanics with chronic hepatitis C. PR Health Sci J 2004; 23(2 Suppl.): 61-67.
57. El SS, Coyle D, Giulivi A, Afzal M. Economic burden of hepatitis C in Canada and the potential impact of prevention: Results from a disease model. European J Health Economics 2005; 6: 159-165.
58. Wong JB, McQuillan GM, McHutchison JG, Poynard T. Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am J Public Health 2000; 90: 1562-1569.
59. Hanouneh IA, Feldstein AE, Lopez R, Yerian L, Pillai A, Zein CO, Zein NN. Clinical significance of metabolic syndrome in the setting of chronic hepatitis C virus infection. Clin Gastroenterol Hepatol 2008; 6: 584-589.
60. Lelutiu-Weinberger C, Pouget ER, Des Jarlais DD, Cooper HL, Scheinmann R, Stern R, et al. A meta-analysis of the hepatitis C virus distribution in diverse racial/ethnic drug injector groups. Social Science & Medicine 2009; 68: 579-590.
61. Schmunis GA, Cruz JR. Safety of the blood supply in Latin America. Clin Microbiol Rev 2005;18: 12-29.
62. Schmunis GA, Zicker F, Pinheiro F, Brandling-Bennett D. Risk for transfusion-transmitted infectious diseases in Central and South America. Emerg Infect Dis 1998; 4: 5-11.
63. Cavalheiro NP, Barone AA, Tengan FM. HCV serotypes in Brazilian patients. Int J Infect Dis 2002; 6: 228-232.
64. Soza A, Arrese M, Gonzalez R, Alvarez M, Perez RM, Cortes P, Patillo A, et al. Clinical and epidemiological features of 147 Chilean patients with chronic hepatitis C. Ann Hepa-tol 2004; 3: 146-151.
65. Rivas-Estilla AM, Cordero-Perez P, Trujillo-Murillo KDC, Ramos-Jimenez J, Chen-Lopez C, Garza-Rodriguez MDL, Ramirez-Gutierrez A, Munoz-Espinosa L. Genotyping of hepatitis C virus (HCV) in infected patients from Northeast Mexico. Ann Hepatol 2008; 7: 144-147.
66. Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P, Nevens F, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997; 112: 463-472.
67. Quiroz ME, Flores YN, Aracena B, Granados-Garcia V, Sal-meron J, Perez R, Cabrera G, et al. Estimating the cost of treating patients with liver cirrhosis at the Mexican Social Security Institute. Sal Pub Mex 2010; 52: 493-501.
68. Merk K, Mattsson B, Mattsson A, Holm G, Gullbring B, Bjor-kholm M. The incidence of cancer among blood donors. Int J Epidemiol 1990; 19: 505-509.
69. Ashour D, Moftah F, Gobran H, Ekram D. Decreasing the risk of transfusion transmitted infections (TTIS) in the Egyptian Blood Transfusion Services. Vox Sanguinis Conference: 19th Regional Congress of the ISBT-Eastern Medi-terreanean and Europe Cairo Egypt Conference Start: 20090321 Conference End: 20090325 Conference: 19th Regional Congress of the ISBT-Eastern Mediterreanean and Europe Cairo Eg 2009; (var. pagings): 103-104.
70. Burguete-Garcia AI, Conde-Gonzalez C, Jimenez-Mendez R, Juarez-Diaz Y, Meda-Monzon E, Torres-Poveda K, et al. Hepatitis C seroprevalence and correlation between viral load and viral genotype among primary care clients in Mexico. Sal Pub Mex 2011; 53(Suppl. 1): S7-S12.
71. El KM, Cordeiro Q, Luz DA, Duarte LS, Gama ME, Corbett CE. Endemic hepatitis B and C virus infection in a Brazilian Eastern Amazon region. Arq Gastroenterol 2010; 47: 35-41.
72. Aquino JA, Pegado KA, Barros LP, Machado LF. Seroprevalence of hepatitis B virus and hepatitis C virus infections among individuals in the State of Para. [Portuguese]. Re-vista Da Sociedade Brasileira de Medicina Tropical 2008; 41: 334-337.
73. Ivantes CA, Silva D, Messias-Reason I. High prevalence of hepatitis C associated with familial history of hepatitis in a small town of south Brazil: efficiency of the rapid test for epidemiological survey. Braz J Infect Dis 2010; 14: 483-488.
74. Gonzalez SA, Keeffe EB. IL-28B As a Predictor of Sustained Virologic Response in Patients with Chronic Hepatitis C Virus Infection. Gastroenterol Hepatol (NY) 2011; 7: 366-373.
75. Ridruejo E, Solano A, Marciano S, Galdame O, Adrover R, Cocozzella D, Delettieres D, et al. Genetic variation in in-terleukin-28B predicts SVR in hepatitis C genotype 1 Argentine patients treated with PEG IFN and ribavirin. Ann Hepatol 2011; 10: 452-457.
76. Burguete-Garcia A, Conde-Gonzalez C, Jimenez-Mendez R, Juarez-Diaz Y, Meda-Monzon E, Torres-Poveda K, et al. Hepatitis C virus surveillance study among primary care attention clients in Mexico: A public health opportunity for an emerging disease. Pharmacoepidemiology and Drug Safety 2011; 20: S186-S187.
77. Malbran C. Taller de Actualización en Hepatitis virales: ¿El conocimiento actual es aplicable en Argentina? Malbran C 2010; Available from: http://www.hepatitisviral.com.ar/ presentaciones/reunion_19/101018epidanlis.ppt.
78. Ridruejo E, Adrover R, Cocozzella D, Fernandez N, Reg-giardo MV. Efficacy, tolerability and safety in the treatment of chronic hepatitis C with combination of PEG-Interferon-Ribavirin in daily practice. Ann Hepatol 2010; 9: 46-51.
79. Lampe E, Espirito-Santo MP, Martins RM, Bello G. Epidemic history of Hepatitis C virus in Brazil. Infect Genet Evol 2010; 10: 886-895.
80. Sawada L, Pinheiro AC, Locks D, Pimenta AS, Rezende PR, Crespo DM, Crescente JA, et al. Distribution of hepatitis C virus genotypes among different exposure categories in the State of Para, Brazilian Amazon. Rev Soc Bras Med Trop 2011; 44:8-12.
81. Campiotto S, Pinho JRR, Carrilho FJ, Da Silva LC, Souto FJD, Spinelli V, Pereira LMMB, et al. Geographic distribution of hepatitis C virus genotypes in Brazil. Brazilian J Medical and Biological Research 2005; 38: 41-49.
82. Romano CM, de Carvalho-Mello IM, Jamal LF, de Melo FL, Ia-marino A, Motoki M, Pinho JR, et al. Social networks shape the transmission dynamics of hepatitis C virus. PLoS ONE 2010; 5: e11170.
83. Mora MV, Romano CM, Gomes-Gouvea MS, Gutierrez MF, Carrilho FJ, Pinho JR. Molecular characterization, distribution, and dynamics of hepatitis C virus genotypes in blood donors in Colombia. J Med Virol 2010; 82: 1889-1898.
84. Burguete-Garcia AI, Conde-Gonzalez C, Jimenez-Mendez R, Juarez-Diaz Y, Meda-Monzon E, Torres-Poveda K, Madrid-Marina V. Hepatitis C seroprevalence and correlation between viral load and viral genotype among primary care clients in Mexico. Sal Pub Mex 2011; 53(Suppl. 1): S7-S12.
85. Sanchez JL, Sjogren MH, Callahan JD, Watts DM, Lucas C, Abdel-Hamid M, Constantine NT, et al. Hepatitis C in Peru: risk factors for infection, potential iatrogenic transmission, and genotype distribution. Am J Trop Med Hyg 2000; 63: 242-248.
86. Pujol FH, Loureiro CL. Replacement of hepatitis C virus genotype 1b by genotype 2 over a 10-year period in Venezuela. J Clinical Gastroenterology 2007; 41: 518-520.